ArticlePediatric cardiology2017
Single-Center Experience Using Selexipag in a Pediatric Population.
Article in Pediatric cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 38 citations in OpenAlex.
- Efficacy and Tolerability of Selexipag in Pediatric Patients with Pulmonary Arterial Hypertension: An Updated Systematic Review and Meta-analysis.Pediatric cardiology · 2025Review
- Selexipag Dosing Strategies for Pediatric Patients with Pulmonary Arterial Hypertension.Pediatric cardiology · 2025Article
- Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration.Frontiers in pediatrics · 2023Article
- A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients.Frontiers in pediatrics · 2023Article
- Treatment of pulmonary arterial hypertension in children.Cardiovascular diagnosis and therapy · 2021Review
- Safety and Tolerability of a Rapid Transition From Intravenous Treprostinil to Oral Selexipag in Three Adolescent Patients With Pulmonary Arterial Hypertension.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021Article
- Drug Treatment of Pulmonary Hypertension in Children.Paediatric drugs · 2020Review
- Diagnosis, Evaluation and Treatment of Pulmonary Arterial Hypertension in Children.Children (Basel, Switzerland) · 2018Review
- Treatment of Pediatric Pulmonary Hypertension.Current treatment options in cardiovascular medicine · 2018Review
- Future Applications of the Selective Prostacyclin (IP) Receptor Agonist Selexipag in Pediatric Pulmonary Hypertension.Pediatric cardiology · 2017Article
- Use of selexipag in a teenage patient with pulmonary arterial hypertension.Annals of pediatric cardiologyArticle
- Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension.Pulmonary circulationArticle
- Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?Pulmonary circulationArticle
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) is a rare and progressive disorder. Current treatment in the pediatric population includes phosphodiesterase 5 inhibitors (PDE-5i), endothelin receptor antagonists (ERA), and both inhaled and intravenous prostacyclin pathway agonists. As of December 22, 2015 the first oral prostacyclin pathway agonist, selexipag (Uptravi
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.